The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
Catherine Lai,1 Adrese Michael Kandahari,1 Chaitra Ujjani2 1Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC, USA; 2Seattle Cancer Care Alliance, Fred Hutchinson CRC, University of Washington, Seattle, WA, USACorrespondence: Catherine LaiLombardi Comprehen...
Guardado en:
Autores principales: | Lai C, Kandahari AM, Ujjani C |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8d0f2aa8840b4083b1f665551c3fda37 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma
por: Illidge T, et al.
Publicado: (2012) -
Hodgkin lymphoma. ASCO, EHA and ASH 2020 news
por: Elena A. Demina
Publicado: (2021) -
Modern possibilities of therapy for primary cutaneous T-cell lymphomas: the first results of the use of brentuximab vedotin in the Russian Federation
por: Liliya G. Gorenkova, et al.
Publicado: (2021) -
Modern approaches in the first line treatment of CD30-positive peripheral T-cell lymphomas
por: Irina V. Poddubnaya, et al.
Publicado: (2021) -
Outcomes and relapse patterns following chemotherapy in advanced Hodgkin lymphoma in the positron emission tomography era
por: Lapuz C, et al.
Publicado: (2018)